A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) (BAF_FRontier-1)
BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies
Sponsor: Eli Lilly and Company
A PHASE1 clinical study on B-cell Lymphoma and Lymphoma, Follicular, this trial is actively recruiting participants. The trial is conducted by Eli Lilly and Company and has accumulated 7 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Mar 2026 — Present [monthly]
Not Yet Recruiting PHASE1
-
Feb 2026 — Mar 2026 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Not Yet Recruiting PHASE1
▶ Show 2 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus, Denmark , Ann Arbor, United States , Aurora, United States , Barcelona, Spain , Berlin, Germany , Bologna, Italy , Boston, United States , Chiba, Japan , Chicago, United States , Cleveland, United States and 35 more locations